Valeant Pharmaceuticals International Inc (VRX.N) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : New Constructs, LLC
$25.00
Provider : Sadif Analytics Prime
$10.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc lowers FY 2014 outlook-Conference Call


Thursday, 31 Jul 2014 08:00am EDT 

Valeant Pharmaceuticals International Inc:Sees FY 2014 revenue in the $8.0 to $8.3 billion range.FY 2014 cash EPS in the $7.90 to $8.10 per share range.FY 2014 revenue of $8.2 bln and EPS of $8.02 - Thomson Reuters I/B/E/S.